KDIGO 2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection?

Ognibene, Agostino; Grandi, G.F. De; Lorubbio, Maria; Rapi, Stefano; Salvadori, Barbara; Terreni, Alessandro; Veroni, Franca

doi:10.1016/j.clinbiochem.2015.07.030

Cited by 16 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The recent introduction of estimated glomerular filtration rate (eGFR) has become an easy method for studying renal function, determined from serum creatinine, age, sex, and race [ 9 ]. At present, we have two major formulae, the equation of chronic kidney disease-epidemiology collaboration (CKD-EPI) [ 10 ] and the modification of diet in renal disease (MDRD-4 or MDRD-IDMS) [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Glomerular Filtration Rate and/or Ratio of Urine Albumin to Creatinine as Markers for Diabetic Retinopathy: A Ten-Year Follow-Up Study

Romero-Aroca

Baget-Bernaldiz

Navarro-Gil

et al. 2018

Journal of Diabetes Research

View full text Add to dashboard Cite

Aims To determine the relationship between diabetic nephropathy and diabetic retinopathy on a population of type 2 diabetes mellitus patients. Methods A prospective ten-year follow-up population-based study. We determined differences between estimated glomerular filtration rate (eGFR) using the chronic kidney disease epidemiology collaboration equation and urine albumin to creatinine ratio. Results Annual incidence of any-DR was 8.21 ± 0.60% (7.06%–8.92%), sight-threatening diabetic retinopathy (STDR) was 2.65 ± 0.14% (2.48%–2.88%), and diabetic macular edema (DME) was 2.21 ± 0.18% (2%–2.49%). Renal study results were as follows: UACR > 30 mg/g had an annual incidence of 7.02 ± 0.05% (6.97%–7.09%), eGFR < 60 ml/min/1.73 m2 incidence was 5.89 ± 0.12% (5.70%–6.13%). Cox's proportional regression analysis of DR incidence shows that renal function studied by eGFR < 60 ml/min/1.73 m2 was less significant (p = 0.04, HR 1.223, 1.098–1.201) than UACR ≥ 300 mg/g (p < 0.001, HR 1.485, 1.103–1.548). The study of STDR shows that eGFR < 60 ml/min/1.73 m2 was significant (p = 0.02, HR 1.890, 1.267–2.820), UACR ≥ 300 mg/g (p < 0.001, HR 2.448, 1.595–3.757), and DME shows that eGFR < 60 ml/min/1.73 m2 was significant (p = 0.02, HR 1.920, 1.287–2.864) and UACR ≥ 300 mg/g (p < 0.001, HR 2.432, 1.584–3.732). Conclusions The UACR has a better association with diabetic retinopathy than the eGFR, although both are important risk factors for diabetic retinopathy.

show abstract

Section: Introductionmentioning

confidence: 99%

Glomerular Filtration Rate and/or Ratio of Urine Albumin to Creatinine as Markers for Diabetic Retinopathy: A Ten-Year Follow-Up Study

Romero-Aroca

Baget-Bernaldiz

Navarro-Gil

et al. 2018

Journal of Diabetes Research

View full text Add to dashboard Cite

show abstract

“…47 In most patients, the first sign of DN is moderately increased urinary albumin excretion, 48,49 which is associated with higher risks of kidney failure 50 (ie, 30e300 mg/g of creatinine in a spot urine sample) (also termed microalbuminuria). 51 A study 52 reported that PF combined with benazepril can significantly improve the clinical symptoms and renal function and reduce UAER of DN. In this study, the levels of Scr, 24-h markers in patients with DN.…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis

Li²,

Peng

et al. 2020

Clinical Therapeutics

View full text Add to dashboard Cite

Purpose: Irbesartan is widely used clinically in the treatment of diabetic nephropathy (DN). It is believed that piperazine ferulate (PF) combined with irbesartan could result in an improved efficacy in the treatment of DN. We present the latest meta-analysis that details the combination of PF and irbesartan therapy. Methods: Before January 31, 2020, we searched various electronic databases for appropriate articles. Our search was not restricted by keyword or language. We then filtered all articles using certain criteria and assessed the quality of the qualified studies. Findings: The meta-analysis included 12 trials that involved 1300 patients (650 in the experimental group and 650 in the control group). The ages of the patients ranged from 30 to 79 years. Compared with irbesartan alone, the total effective rate of PF combined with irbesartan was significantly higher (odds ratio [OR] ¼ 4.95; 95% CI, 3.11e7.58; P < 0.0001). The blood glucose level was controlled by significantly decreasing the fasting plasma glucose level (mean difference [MD] ¼ −1.40; 95% CI, −2.70 to −0.11; P ¼ 0.03) and 2-h plasma glucose level (MD ¼ −1.65; 95% CI, −2.49 to −0.82; P < 0.0001). The combination therapy significantly decreased the levels of serum creatinine (MD ¼ −10.24; 95% CI, −15.25 to −5.23; P < 0.0001), 24-h urinary protein (MD ¼ −0.

show abstract

“…mCrCl overestimates mGFR due to creatinine secretion. 130 The magnitude of overestimation is 15% or more at normal GFR, based on older data using nonstandardized serum creatinine assays. The magnitude of overestimation may be higher using standardized assays.…”

Section: Measurement Methodsmentioning

confidence: 99%

Survival in Living Kidney Donors: An Australian and New Zealand Cohort Study Using Data Linkage

Mata

Clayton

Kelly

et al. 2020

Transplantation Direct

View full text Add to dashboard Cite

The 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors is intended to assist medical professionals who evaluate living kidney donor candidates and provide care before, during and after donation. The guideline development process followed the Grades of Recommendation Assessment, Development, and Evaluation (GRADE) approach and guideline recommendations are based on systematic reviews of relevant studies that included critical appraisal of the quality of the evidence and the strength of recommendations. However, many recommendations, for which there was no evidence or no systematic search for evidence was undertaken by the Evidence Review Team, were issued as ungraded expert opinion recommendations. The guideline work group concluded that a comprehensive approach to risk assessment should replace decisions based on assessments of single risk factors in isolation. Original data analyses were undertaken to produce a "proof-in-concept" risk-prediction model for kidney failure to support a framework for quantitative risk assessment in the donor candidate evaluation and defensible shared decision making. This framework is grounded in the simultaneous consideration of each candidate's profile of demographic and health characteristics. The processes and framework for the donor candidate evaluation are presented, along with recommendations for optimal care before, during, and after donation. Limitations of the evidence are discussed, especially regarding the lack of definitive prospective studies and clinical outcome trials. Suggestions for future research, including the need for continued refinement of long-term risk prediction and novel approaches to estimating donation-attributable risks, are also provided.

show abstract

KDIGO 2012 Clinical Practice Guideline CKD classification rules out creatinine clearance 24 hour urine collection?

Cited by 16 publications

References 20 publications

Glomerular Filtration Rate and/or Ratio of Urine Albumin to Creatinine as Markers for Diabetic Retinopathy: A Ten-Year Follow-Up Study

Glomerular Filtration Rate and/or Ratio of Urine Albumin to Creatinine as Markers for Diabetic Retinopathy: A Ten-Year Follow-Up Study

Therapeutic Efficacy of Piperazine Ferulate Combined With Irbesartan in Diabetic Nephropathy: A Systematic Review and Meta-analysis

Survival in Living Kidney Donors: An Australian and New Zealand Cohort Study Using Data Linkage

Contact Info

Product

Resources

About